Hemosol B0 (Calcium, Lactic Acid, Magnesium, Sodium, Chloride Ion, Hydrogen Carbonate)

The solution delivers calcium, magnesium, sodium, chloride, bicarbonate and lactic acid directly into the bloodstream or dialysis circuit. These ions dissolve and integrate into the extracellular fluid, restoring normal electrolyte concentrations and buffering capacity. Bicarbonate and lactate act as pH buffers, while calcium and magnesium support cardiac and neuromuscular function, collectively correcting the disturbances seen in dialysis or fluid loss.

Dosing of Hemosol B0 is individualized. The prescribing clinician determines the volume and rate based on the patient’s current electrolyte profile, fluid status, and the specific requirements of the dialysis session or intravenous therapy. No fixed regimen is provided; dosage is adjusted to achieve target laboratory values and clinical goals.

Safety data for Hemosol B0 in pregnancy and lactation are limited. Because it contains essential electrolytes, it may be used when the potential benefit outweighs any theoretical risk, but the decision must be made by the treating physician after careful consideration of maternal and fetal health.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with standard bicarbonate‑based dialysis fluids, Hemosol B0 adds calcium, magnesium and lactate, offering a more comprehensive electrolyte profile. This can reduce the need for supplemental infusions during treatment. However, the choice depends on the patient’s individual electrolyte needs, the dialysis protocol and institutional preferences.

Hemosol B0 should be stored at ambient temperature, preferably below 25 °C. Keep the container sealed, protect it from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze the solution, and inspect the vial for any particulate matter before use.

The solution is administered either as part of the haemodialysis circuit, where it mixes with the dialysate, or as an intravenous infusion through a calibrated infusion set. Administration rate is set by the clinician according to the patient’s electrolyte targets and overall fluid balance.

Serious risks include severe hypermagnesemia, metabolic alkalosis, anaphylactic reactions and electrolyte overload that can precipitate cardiac arrhythmias. Continuous monitoring of serum electrolytes and acid‑base status during therapy helps detect these complications early.

Patients with known hypersensitivity to any component of the solution should avoid it. Caution is also advised for individuals with uncontrolled cardiac disease, severe renal impairment not on dialysis, or those already receiving high‑dose electrolyte supplements that could lead to overload.